Supplementary table II. Effectiveness of dupilumab, estimated probability over time

Published: 09-07-2020| Version 1 | DOI: 10.17632/nmmz5rrmd9.1
Contributor:
Angela Bosma

Description

Scores displayed for ‘median’ patient: male, 41 years old, BMI 25, Fitzpatrick skin type 2, no usage of concomitant medication; IGA, Investigator Global Assessment; NRS, Numerical Rating Scale; Estimated probability ranging from 0 to 100% for the answer categories based on our ordinal logistic mixed-effects models; a Registered in the Amsterdam UMC only.

Files